Recent advances in cancer cell bionic nanoparticles for tumour therapy

Abstract

Nanoparticle-based drug delivery systems have found extensive use in delivering oncology therapeutics; however, some delivery vehicles still exhibit rapid immune clearance, lack of biocompatibility and insufficient targeting. In recent years, bionanoparticles constructed from tumour cell membranes have gained momentum as tumour-targeting therapeutic agents. Cancer cell membrane-coated nanoparticles (CCMCNPs) typically consist of a drug-loaded nanoparticle core coated with cancer cell membrane. CCMCNPs retain homologous tumour cell surface antigens, receptors and proteins, and it has been shown that the modified nanoparticles exhibit better homologous targeting, immune escape and biocompatibility. CCMCNPs are now widely used in a variety of cancer treatments, including photothermal, photodynamic and sonodynamic therapies, chemotherapy, immunotherapy, chemodynamical therapy or other combination therapies. This article presents different therapeutic approaches using multimodal antitumour therapy—combination of two or more therapies that treat tumours synergistically—based on tumour cell membrane systems. The advantages of CCMCNPs in different cancer treatments in recent years are summarised, thus, providing new strategies for cancer treatment research.

Keywords:

• Tumour cells
• bionic nanoparticles
• nanoparticles
• multimodal antitumour therapy

Acknowledgements

We thank the current and former members of our laboratories and collaborators for their contributions to the publications cited in this review article.

Authors’ contributions

All authors contributed to the study conception and design. The first draft of the manuscript was written by Wanting Jiang and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

No data was used for the research described in this article.

Additional information

Funding

This work was supported by the Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine under Grant number [202302]; Natural Science Foundation of China under Grant number [81573621]; Science and Technology Innovation Program of Hunan Province under Grant number [2021RC4064]; and 2021 Hunan University of Chinese Medicine Graduate Innovation Project under Grant number [2021CX09].